Results 241 to 250 of about 27,891 (280)

A highly sensitive micelle-enhanced synchronous spectrofluorimetric determination of the recently approved co-formulated drugs, bilastine and montelukast in pharmaceuticals and human plasma at nanogram levels.

Luminescence (Chichester, England Print), 2023
In this study, the simultaneous determination of bilastine and montelukast, two recently approved co-formulated antihistaminic medications, was accomplished using a quick, sensitive, environmentally friendly, and reasonably priced synchronous ...
Galal Magdy, Mohamed A. El Hamd, Mahmoud H. El-Maghrabey, F. M. Zainy, W. Mahdi, Sultan Alshehri, W. T. Alsaggaf, A. Radwan   +7 more
semanticscholar   +1 more source

Montelukast Ameliorates Scopolamine-induced Alzheimer's Disease: Role on Cholinergic Neurotransmission, Antioxidant Defence System, Neuroinflammation and Expression of BDNF.

CNS and Neurological Disorders - Drug Targets, 2023
BACKGROUND Alzheimer's disease (AD) is an overwhelming neurodegenerative disease with progressive loss of memory. AD is characterized by the deposition of the senile plaques mainly composed of β-amyloid (Aβ) fragment, BDNF decline, Cholinergic system ...
Bhavana Yerraguravagari, Naga Pavani Penchikala, Aravinda Sai Kolusu, Grandhi Sandeep Ganesh, Prasad Konduri, Kumar V S Nemmani, P. Samudrala   +6 more
semanticscholar   +1 more source

Montelukast

Drugs, 1998
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. In patients with asthma, montelukast 5 to 250 mg/day attenuated LTD4-induced bronchoconstriction and, at a dosage of 10 mg, significantly reduced early and late airway response to allergen (dust mite extract) relative to placebo.
Anthony Markham, Diana Faulds
openaire   +5 more sources

Montelukast and neuropsychiatric events – a sequence symmetry analysis

Journal of Asthma, 2022
Objectives Neuropsychiatric events (NEs) reported with montelukast during post-marketing surveillance by the US Food & Drug Administration resulted in a 2008 safety alert and a black box warning in 2020. Our objective was to evaluate montelukast exposure
Christopher W Fox, Chelsea Khaw, A. Gerke, B. Lund   +3 more
semanticscholar   +1 more source

Neuropsychiatric reactions with the use of montelukast

British medical journal, 2022
• Montelukast, used in the treatment of asthma and allergic rhinitis, can cause serious mental health adverse effects such as nightmares, aggression, depression, and suicidal ideation • These adverse effects have been reported in patients of all ages ...
C. Ekhart, Florence van Hunsel, Vanessa Sellick, T. D. de Vries   +3 more
semanticscholar   +1 more source

Suicidality and montelukast

Expert Opinion on Drug Safety, 2009
Suicide is a serious public health problem. Prevention of suicide depends to a great degree on identification and mitigation of its risk factors. Allergy has been associated with mood and anxiety disorders, risk factors for suicidality. Antiallergic medication could modulate or mediate these predictive associations.
Jong-Min Woo, Partam Manalai, Teodor T. Postolache   +2 more
openaire   +3 more sources

Risk Assessment-Based Enhanced Analytical Quality by Design Approach to Eco-Friendly and Economical Multicomponent Spectrophotometric Methods for Simultaneous Estimation of Montelukast Sodium and Bilastine.

Journal of AOAC International, 2021
BACKGROUND The concomitant montelukast and bilastine are used as additive therapy for seasonal allergic rhinoconjuctivitis and mild to moderate asthma. According to the literature review, no UV-visible spectrophotometry method has been reported yet for ...
Pintu B. Prajapati, Jayesh Tamboli, Parth Surti, Ashish Mishra   +3 more
semanticscholar   +1 more source